NEXT Oncology

Running trials

• Not yet recruiting

  A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors

  NCT07909356· Phase 1· Source

• Recruiting

  A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07719361· Phase 1· Source

• Recruiting

  A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

  NCT07705334· Phase 1· Source

• Recruiting

  A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

  NCT07458347· Phase 1· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  NCT07397338· Phase 1/2· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Source

• Recruiting

  A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07244341· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  NCT07223047· Phase 1/2· Source

• Recruiting

  M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

  NCT07166601· Phase 1· Source

• Recruiting

  PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

  NCT07190469· Phase 1· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  NCT07090499· Phase 1· Source

• Recruiting

  A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

  NCT06997029· Phase 1· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Source

• Recruiting

  STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

  NCT06975293· Phase 1/2· Source

• Recruiting

  A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

  NCT06907043· Phase 1/2· Source

• Recruiting

  BBO-11818 in Adult Subjects With KRAS Mutant Cancer

  NCT06917079· Phase 1· Source

• Recruiting

  First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

  NCT06799065· Phase 1/2· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

  NCT06720987· Phase 1· Source

• Recruiting

  A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  NCT06413680· Phase 1/2· Source

• Active, not recruiting

  Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

  NCT06577987· Phase 1· Source

• Recruiting

  Study of STP938 (Dencatistat) in Advanced Solid Tumours

  NCT06297525· Phase 1· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

  NCT06440005· Phase 1· Source

• Recruiting

  Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  NCT06239194· Phase 1/2· Source

• Recruiting

  This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

  NCT06451497· Phase 1· Source

• Recruiting

  A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

  NCT06385925· Phase 1/2· Source

• Recruiting

  BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

  NCT06120283· Phase 1· Source

• Recruiting

  A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

  NCT06090266· Phase 1/2· Source

• Recruiting

  A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06067841· Phase 1· Source

• Active, not recruiting

  A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

  NCT05787587· Phase 1· Source

• Recruiting

  Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

  NCT05784688· Phase 1/2· Source

• Active, not recruiting

  A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

  NCT05731271· Phase 1/2· Source

• Active, not recruiting

  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

  NCT05585320· Phase 1/2· Source

• Active, not recruiting

  Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

  NCT05462717· Phase 1· Source

• Active, not recruiting

  Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

  NCT05464030· Phase 1· Source

• Recruiting

  Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT05379985· Phase 1/2· Source

• Active, not recruiting

  P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

  NCT05239143· Phase 1· Source

• Active, not recruiting

  A Study of NDI 1150-101 in Patients With Solid Tumors

  NCT05128487· Phase 1/2· Source

• Active, not recruiting

  Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

  NCT04794699· Phase 1· Source

• Recruiting

  Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

  NCT04665206· Phase 1/2· Source

• Recruiting

  Study of PF-07248144 in Advanced or Metastatic Solid Tumors

  NCT04606446· Phase 2· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

  NCT04526691· Phase 1· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Source

• Active, not recruiting

  A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

  NCT03611868· Phase 1/2· Source

• Recruiting

  A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  NCT03460977· Phase 1· Source

• Active, not recruiting

  First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

  NCT03401385· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer17 recruiting
• Pancreatic cancer14 recruiting
• Colorectal cancer13 recruiting
• Prostate cancer9 recruiting
• Ovarian cancer5 recruiting
• Sarcoma5 recruiting
• Liver and biliary tract cancer4 recruiting
• Triple-negative breast cancer4 recruiting
• Bladder cancer3 recruiting
• Endometrial cancer3 recruiting
• Gastric and esophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• Kidney cancer3 recruiting
• Melanoma3 recruiting
• Mesothelioma3 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Metastatic breast cancer2 recruiting
• Cervical cancer1 recruiting
• Follicular lymphoma1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

  NCT07408089· Phase 1· Source

• Recruiting

  A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  NCT06774963· Phase 1· Source

• Terminated

  First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

  NCT06625515· Phase 1· Source

• Terminated

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· Phase 1· Source

• Terminated

  A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

  NCT06448364· Phase 1· Source

• Terminated

  A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

  NCT06257758· Phase 1/2· Source

• Terminated

  Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

  NCT06052852· Phase 1· Source

• Terminated

  A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

  NCT05917470· Phase 1/2· Source

• Terminated

  Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

  NCT05827614· Phase 1· Source

• Completed

  A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

  NCT05753722· Phase 1· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Source

• Completed

  Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

  NCT05479812· Phase 1· Source

• Completed

  Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

  NCT05259696· Phase 1/2· Source

• Terminated

  Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

  NCT05228015· Phase 1· Source

• Completed

  Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

  NCT04902872· Phase 1/2· Source

• Completed

  Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

  NCT04672434· Phase 1· Source

• Recruiting

  Evaluate the Safety and Clinical Activity of HH2853

  NCT04390737· Phase 1/2· Source

• Completed

  TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

  NCT04306900· Phase 1· Source

• Recruiting

  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  NCT04198766· Phase 1/2· Source

• Terminated

  Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

  NCT04171141· Phase 1· Source

• Terminated

  Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

  NCT04152018· Phase 1· Source

• Completed

  Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

  NCT04121676· Phase 1· Source

• Completed

  A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

  NCT03821233· Phase 1· Source

• Recruiting

  Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

  NCT03715933· Phase 1· Source

• Completed

  PRS-343 in HER2-Positive Solid Tumors

  NCT03330561· Phase 1· Source

• Completed

  Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

  NCT02635672· Phase 1· Source